Lilly Partners With Amplitude Therapeutics on Infectious Disease Vaccines
Eli Lilly struck a deal with RNA drug startup Amplitude Therapeutics to develop trans-amplifying infectious disease vaccines. The companies said the approach could make vaccines easier to manufacture and enable stronger potency in lower doses, potentially improving access and efficiency without reporting any regulatory outcome or financial terms.